Thiazovivin (SKU A5506): Practical ROCK Inhibitor Workflow

Thiazovivin is a small-molecule ROCK inhibitor for workflows in which cell dissociation stress, poor attachment, or inefficient reprogramming limits experimental performance. The product dossier identifies the compound as N-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide, with CAS No. 1226056-71-8 and a molecular weight of 311.36. The Thiazovivin page from APExBIO lists a purity of 98.00% and describes research applications in fibroblast reprogramming and human embryonic stem cell handling.

What This Product Solves

Two practical problems define the intended use of Thiazovivin. First, fibroblast reprogramming can produce a low number of viable, successfully converted cells. The dossier reports that Thiazovivin significantly enhances reprogramming efficiency when used with other inhibitors, including SB 431542 and PD 0325901. This makes it a candidate fibroblast reprogramming enhancer within a defined induced pluripotent stem cell generation workflow, not a substitute for the complete reprogramming system.

Second, enzymatic dissociation can reduce the survival and recovery of human embryonic stem cells. The dossier describes improved hESC survival after trypsinization. In practice, this makes Thiazovivin relevant during cell handling steps where attachment and post-dissociation recovery are measured. Because Thiazovivin is described as a ROCK inhibitor, it may be incorporated into experiments examining the ROCK signaling pathway, but the supplied information does not establish isoform selectivity, a complete target profile, or a universal treatment schedule.

For related background, Thiazovivin: ROCK Inhibitor for Enhanced Cell Reprogramming provides broader context on the same reprogramming and survival applications. For scenario-based troubleshooting, Thiazovivin (SKU A5506): Enhancing Cell Reprogramming and Cell Survival complements this article by focusing on assay design and cell-viability problems.

Protocol Parameters

The following values are product-dossier specifications unless explicitly identified as a workflow recommendation. No fixed biological dose or exposure duration is supplied, so those parameters should not be inferred from the solubility or storage data.

• Assay or use case: Compound identity and calculation basis. Value: Molecular weight 311.36 g/mol; CAS No. 1226056-71-8. Applicability: Stock preparation, dilution calculations, and batch documentation. Rationale: Correct identity and molecular-weight records reduce formulation and transcription errors. Evidence basis: product dossier.
• Assay or use case: DMSO stock formulation. Value: Soluble at concentrations ≥15.55 mg/mL in DMSO. Applicability: Preparation of a concentrated research stock before dilution into the selected culture system. Rationale: This is a formulation reference, not a recommended cellular working concentration; inspect the stock for complete dissolution before use. Evidence basis: product dossier.
• Assay or use case: Solid-compound storage. Value: Typically stored at −20°C. Applicability: Unreconstituted material and retained solid stock. Rationale: Maintaining the stated storage condition supports consistent handling between experiments. Evidence basis: product dossier.
• Assay or use case: Reprogramming or stem-cell survival treatment. Value: Working concentration and exposure duration are not specified in the supplied dossier. Applicability: All cell-based experiments. Rationale: Dose and timing depend on cell type, dissociation method, medium, density, and the other inhibitors in the design; establish them with a controlled pilot. Evidence basis: workflow recommendation based on the stated information boundary.
• Assay or use case: Solution handling. Value: Use prepared solutions promptly; long-term solution storage is not recommended. Applicability: DMSO stocks and working dilutions. Rationale: Limiting storage time and repeated handling helps preserve activity and reduces uncertainty caused by degradation or contamination. Evidence basis: product dossier.
• Assay or use case: Material quality check. Value: 98.00% purity. Applicability: Lot acceptance and experimental records. Rationale: Purity should be recorded when comparing lots or interpreting unexpected cell responses. Evidence basis: product dossier.

Workflow Setup and QC Checklist

Stock preparation

1. Confirm the vial label, SKU A5506, compound identity, lot information, and storage history before opening. Allow the container to equilibrate only as needed to avoid unnecessary condensation and repeated temperature cycling.
2. Prepare the DMSO stock using the molecular weight and the intended stock concentration. The reported solubility of ≥15.55 mg/mL in DMSO indicates a formulation capability; it does not define the concentration that cells should receive.
3. Mix until the material is visibly dissolved. If particulate matter, haze, or precipitation remains, do not proceed directly to cells. Check weighing, solvent quality, concentration calculation, and temperature history first.
4. Label the preparation with concentration, solvent, date, operator, and intended use. Prepare only the amount reasonably required because long-term storage of solutions is not recommended.

Cell-based setup

Define the biological question before adding the compound. For induced pluripotent stem cell generation, compare the complete reprogramming condition with a matched condition lacking Thiazovivin while keeping starting cell state, density, medium, and handling time consistent. If SB 431542 or PD 0325901 is included, document the full combination rather than attributing the outcome to Thiazovivin alone.

For human embryonic stem cell survival studies, include a vehicle control and a no-dissociation or baseline control when scientifically appropriate. Keep the DMSO contribution matched across wells or dishes. Record the dissociation reagent, cell recovery time, attachment conditions, morphology, and viability endpoint. A useful QC sequence is: confirm stock clarity, verify vehicle matching, inspect cells immediately after plating, and reassess recovery using the same endpoint across all conditions.

Documentation

• Record lot, purity, storage condition, stock concentration, solvent, preparation date, and freeze-thaw history.
• Use consistent passage range, cell density, dissociation exposure, and medium-change timing within a comparison.
• Predefine acceptance criteria for attachment, viability, colony formation, or reprogramming readouts before reviewing treatment groups.
• Include independent biological repeats rather than relying on a single high-performing culture.

Common Failure Modes and Fixes

Low post-trypsinization recovery

First check whether the problem is caused by excessive dissociation, delayed plating, unsuitable matrix, poor medium conditioning, or inconsistent cell density. Confirm that the vehicle is present at the same level in every comparison. Thiazovivin may support survival in this context, but it cannot correct severe mechanical or enzymatic damage. Optimize handling variables before increasing compound exposure.

Inconsistent reprogramming performance

Review the starting fibroblast state, passage history, transduction or factor-delivery consistency, and timing of medium changes. Confirm that the intended inhibitor combination was prepared correctly. Because the dossier does not provide a universal concentration or schedule, avoid transferring an unverified condition between cell types without a pilot matrix.

Precipitation or apparent loss of activity

Inspect the DMSO stock before dilution and the final medium after dilution. Precipitation can result from calculation errors, inadequate mixing, solvent incompatibility, or exceeding the practical solubility of the formulation. If the preparation has been stored for an extended period, replace it with a freshly prepared solution rather than assuming activity is unchanged.

Unexpected cytotoxicity

Separate compound-related effects from vehicle effects by using a matched vehicle control. Check cell density, medium composition, exposure timing, and the health of the untreated control. A high-purity material can still produce an unfavorable response if the concentration or exposure is unsuitable for the model. Establish the tolerated range empirically with the smallest practical pilot design.

Scope and Limitations

No directly matched paper evidence is available in the supplied brief for a specific cell line, dose, exposure duration, or quantitative outcome. Accordingly, this article reports the product dossier’s stated uses and specifications without adding invented efficiency values or citation claims. The available information supports use as a research ROCK inhibitor in fibroblast reprogramming and hESC handling, but it does not establish selectivity, pharmacokinetics, clinical benefit, or performance in unrelated assays.

Thiazovivin should not be treated as a universal reagent for every stem cell research workflow. Results may vary with cell source, matrix, dissociation method, culture medium, passage state, inhibitor combinations, and endpoint definition. The material is supplied for scientific research use only and is not intended for diagnostic or medical purposes.

Conclusion

Thiazovivin (SKU A5506) is best deployed as a controlled variable in cell-survival and reprogramming workflows. Use the stated DMSO solubility, −20°C solid storage condition, 98.00% purity, and prompt solution-use guidance for material control; determine biological concentration and timing through cell-specific validation. Matched vehicle controls, consistent dissociation procedures, fresh solutions, and complete batch records are the most practical safeguards for interpretable results.